Development and validation of a hypoxia-stemness-based prognostic signature in pancreatic adenocarcinoma
- PMID: 35935823
- PMCID: PMC9350896
- DOI: 10.3389/fphar.2022.939542
Development and validation of a hypoxia-stemness-based prognostic signature in pancreatic adenocarcinoma
Abstract
Background: Pancreatic adenocarcinoma (PAAD) is one of the most aggressive and fatal gastrointestinal malignancies with high morbidity and mortality worldwide. Accumulating evidence has revealed the clinical significance of the interaction between the hypoxic microenvironment and cancer stemness in pancreatic cancer progression and therapies. This study aims to identify a hypoxia-stemness index-related gene signature for risk stratification and prognosis prediction in PAAD. Methods: The mRNA expression-based stemness index (mRNAsi) data of PAAD samples from The Cancer Genome Atlas (TCGA) database were calculated based on the one-class logistic regression (OCLR) machine learning algorithm. Univariate Cox regression and LASSO regression analyses were then performed to establish a hypoxia-mRNAsi-related gene signature, and its prognostic performance was verified in both the TCGA-PAAD and GSE62452 corhorts by Kaplan-Meier and receiver operating characteristic (ROC) analyses. Additionally, we further validated the expression levels of signature genes using the TCGA, GTEx and HPA databases as well as qPCR experiments. Moreover, we constructed a prognostic nomogram incorporating the eight-gene signature and traditional clinical factors and analyzed the correlations of the risk score with immune infiltrates and immune checkpoint genes. Results: The mRNAsi values of PAAD samples were significantly higher than those of normal samples (p < 0.001), and PAAD patients with high mRNAsi values exhibited worse overall survival (OS). A novel prognostic risk model was successfully constructed based on the eight-gene signature comprising JMJD6, NDST1, ENO3, LDHA, TES, ANKZF1, CITED, and SIAH2, which could accurately predict the 1-, 3-, and 5-year OS of PAAD patients in both the training and external validation datasets. Additionally, the eight-gene signature could distinguish PAAD samples from normal samples and stratify PAAD patients into low- and high-risk groups with distinct OS. The risk score was closely correlated with immune cell infiltration patterns and immune checkpoint molecules. Moreover, calibration analysis showed the excellent predictive ability of the nomogram incorporating the eight-gene signature and traditional clinical factors. Conclusion: We developed a hypoxia-stemness-related prognostic signature that reliably predicts the OS of PAAD. Our findings may aid in the risk stratification and individual treatment of PAAD patients.
Keywords: cancer stemness; hypoxia microenvironment; mRNAsi; pancreatic adenocarcinoma; prognosis.
Copyright © 2022 Tian, Zheng, Mou, Lu, Chen, Du, Zheng, Chen, Shen, Li and Wang.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures










Similar articles
-
Identification of a Four Cancer Stem Cell-Related Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival of Pancreatic Adenocarcinoma.Comb Chem High Throughput Screen. 2022;25(12):2070-2081. doi: 10.2174/1386207325666220113142212. Comb Chem High Throughput Screen. 2022. PMID: 35048799
-
Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.Inflammation. 2022 Aug;45(4):1732-1751. doi: 10.1007/s10753-022-01657-6. Epub 2022 Mar 23. Inflammation. 2022. PMID: 35322324
-
Identification of a Nine-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival of Pancreatic Cancer.Front Oncol. 2019 Sep 27;9:996. doi: 10.3389/fonc.2019.00996. eCollection 2019. Front Oncol. 2019. PMID: 31612115 Free PMC article.
-
Prognostic Value of a Stemness Index-Associated Signature in Primary Lower-Grade Glioma.Front Genet. 2020 May 5;11:441. doi: 10.3389/fgene.2020.00441. eCollection 2020. Front Genet. 2020. PMID: 32431729 Free PMC article.
-
Using ESTIMATE algorithm to establish an 8-mRNA signature prognosis prediction system and identify immunocyte infiltration-related genes in Pancreatic adenocarcinoma.Aging (Albany NY). 2020 Mar 17;12(6):5048-5070. doi: 10.18632/aging.102931. Epub 2020 Mar 17. Aging (Albany NY). 2020. PMID: 32181755 Free PMC article.
Cited by
-
Profiling of a novel circadian clock-related prognostic signature and its role in immune function and response to molecular targeted therapy in pancreatic cancer.Aging (Albany NY). 2023 Jan 9;15(1):119-133. doi: 10.18632/aging.204462. Epub 2023 Jan 9. Aging (Albany NY). 2023. PMID: 36626244 Free PMC article.
-
Comprehensive analysis of bulk and single-cell transcriptomic data reveals a novel signature associated with endoplasmic reticulum stress, lipid metabolism, and liver metastasis in pancreatic cancer.J Transl Med. 2024 Apr 29;22(1):393. doi: 10.1186/s12967-024-05158-y. J Transl Med. 2024. PMID: 38685045 Free PMC article.
-
Beyond ENO1, emerging roles and targeting strategies of other enolases in cancers.Mol Ther Oncolytics. 2023 Nov 10;31:100750. doi: 10.1016/j.omto.2023.100750. eCollection 2023 Dec 19. Mol Ther Oncolytics. 2023. PMID: 38075246 Free PMC article. Review.
-
Characterization of cancer-associated fibroblasts (CAFs) and development of a CAF-based risk model for triple-negative breast cancer.Cancer Cell Int. 2023 Nov 25;23(1):294. doi: 10.1186/s12935-023-03152-w. Cancer Cell Int. 2023. PMID: 38007443 Free PMC article.
-
Hypoxia-related bioinformatic signatures associated with prognosis and tumor microenvironment of pancreatic cancer: Current status, concerns, and future perspectives.World J Gastroenterol. 2024 Nov 28;30(44):4689-4696. doi: 10.3748/wjg.v30.i44.4689. World J Gastroenterol. 2024. PMID: 39610772 Free PMC article. Review.
References
-
- Abou Khouzam R., Rao S. P., Venkatesh G. H., Zeinelabdin N. A., Buart S., Meylan M., et al. (2021). An eight-gene hypoxia signature predicts survival in pancreatic cancer and is associated with an immunosuppressed tumor microenvironment. Front. Immunol. 12, 680435. 10.3389/fimmu.2021.680435 - DOI - PMC - PubMed
-
- Aglietta M., Barone C., Sawyer M. B., Moore M. J., Miller W. H., Bagala C., et al. (2014). A phase I dose escalation trial of tremelimumab (CP-675, 206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Ann. Oncol. 25 (9), 1750–1755. 10.1093/annonc/mdu205 - DOI - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous